133 related articles for article (PubMed ID: 19050794)
1. Angiogenesis and co-expressed of ER and c-erbB-2 (HER2/neu) protein in primary breast cancer patients: an analysis of 158 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2008; 49(4):469-78. PubMed ID: 19050794
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2007; 48(2):121-9. PubMed ID: 17641798
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis and progesterone receptor status in primary breast cancer patients: an analysis of 158 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2007; 48(3):267-74. PubMed ID: 17914494
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis and tumor grading in primary breast cancer patients: an analysis of 158 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2006; 47(3):251-7. PubMed ID: 17308684
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis and ER/PR status in primary breast cancer patients: an analysis of 158 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2007; 48(1):25-31. PubMed ID: 17502947
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis and tumor histologic type in primary breast cancer patients: an analysis of 155 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2008; 49(2):181-8. PubMed ID: 18516324
[TBL] [Abstract][Full Text] [Related]
7. Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor?
Jacobs TW; Siziopikou KP; Prioleau JE; Raza S; Baum JK; Hayes DF; Schnitt SJ
Mod Pathol; 1998 Mar; 11(3):259-64. PubMed ID: 9521472
[TBL] [Abstract][Full Text] [Related]
8. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression.
Barnes PJ; Boutilier R; Chiasson D; Rayson D
Breast Cancer Res Treat; 2005 May; 91(2):173-8. PubMed ID: 15868445
[TBL] [Abstract][Full Text] [Related]
9. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.
McCarthy NJ; Yang X; Linnoila IR; Merino MJ; Hewitt SM; Parr AL; Paik S; Steinberg SM; Hartmann DP; Mourali N; Levine PH; Swain SM
Clin Cancer Res; 2002 Dec; 8(12):3857-62. PubMed ID: 12473600
[TBL] [Abstract][Full Text] [Related]
10. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
11. HER2/neu expression in relation to clinicopathologic features of breast cancer patients.
Traina A; Agostara B; Marasà L; Calabrò M; Zarcone M; Carruba G
Ann N Y Acad Sci; 2006 Nov; 1089():159-67. PubMed ID: 17261764
[TBL] [Abstract][Full Text] [Related]
12. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.
D'Alessandro C; Dellapasqua S; Orlando L; Santoro L; Maisonneuve P; Torrisi R; Balduzzi A; Scarano E; Ghisini R; Peruzzotti G; Goldhirsch A; Colleoni M
Breast J; 2008; 14(5):435-41. PubMed ID: 18821931
[TBL] [Abstract][Full Text] [Related]
13. Optimizing microvessel counts according to tumor zone in invasive ductal carcinoma of the breast.
Jitsuiki Y; Hasebe T; Tsuda H; Imoto S; Tsubono Y; Sasaki S; Mukai K
Mod Pathol; 1999 May; 12(5):492-8. PubMed ID: 10349987
[TBL] [Abstract][Full Text] [Related]
14. Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer.
Chan JK; Loizzi V; Magistris A; Lin F; Rutgers J; Osann K; Disaia PJ; Berman ML
Clin Cancer Res; 2004 Dec; 10(24):8538-43. PubMed ID: 15623636
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
Lindemann K; Resau J; Nährig J; Kort E; Leeser B; Annecke K; Welk A; Schäfer J; Vande Woude GF; Lengyel E; Harbeck N
Histopathology; 2007 Jul; 51(1):54-62. PubMed ID: 17593080
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients.
Dillon MF; Stafford AT; Kelly G; Redmond AM; McIlroy M; Crotty TB; McDermott E; Hill AD; Young LS
Endocr Relat Cancer; 2008 Sep; 15(3):745-53. PubMed ID: 18469157
[TBL] [Abstract][Full Text] [Related]
17. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
18. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
[TBL] [Abstract][Full Text] [Related]
19. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls.
Moriki T; Takahashi T; Ueta S; Mitani M; Ichien M
Diagn Cytopathol; 2004 Apr; 30(4):251-6. PubMed ID: 15048960
[TBL] [Abstract][Full Text] [Related]
20. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.
Shah SS; Wang Y; Tull J; Zhang S
Diagn Mol Pathol; 2009 Mar; 18(1):30-3. PubMed ID: 19214111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
